多反应性皮克林乳液稳定于两性纤维素纳米晶体,用于构建疏水药物的智能释放系统
Keran Li1, Lifei Peng2, Jing Li2
1College of Chemistry and Chemical Engineering, Southwest Petroleum University, Chengdu 610500, PR China; State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu 610500, PR China.
Carbohydrate polymers
|March 4, 2025
概括
纤维素纳米晶纳米颗粒稳定皮克林乳液,增强黄素的生物可用性. 这些智能纳米粒子对pH和温度等刺激做出反应,在药物输送中显示了广泛的应用.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
- 合体和表面化学
背景情况:
- 纤维素纳米晶 (CNC) 是从生物质中获得的可持续纳米材料.
- 开发响应刺激的皮克林乳液对于先进的输送系统至关重要.
- 花生提供了一个新的来源,用于纤维素纳米晶提取.
研究的目的:
- 通过将DMAEMA和MAA接种在CNC上,合成响应多刺激的纳米粒子 (CNC/PDM).
- 为了利用CNC/PDM纳米颗粒稳定皮克林乳液.
- 评估这些皮克林乳液在稳定性,响应性和药物输送应用方面的性能.
主要方法:
- 从花生中提取纤维素纳米晶体 (CNC).
- 将DMAEMA和MAA单体移植到CNC上,使用RAFT聚合形成CNC/PDM纳米粒子.
- 用CNC/PDM稳定的皮克林乳液的制备和表征.
- 研究不同pH值下的乳液稳定性,纳米颗粒度,水与油的比率以及油的极性.
- 评估乳液对pH,温度和CO2刺激的反应.
- 黄素的封装和封装效率 (EE) 的确定.
- 在体外消化研究评估黄素释放和生物可访问性.
主要成果:
- 成功合成了响应多刺激的CNC/PDM纳米粒子.
- 使用CNC/PDM开发出稳定的皮克林乳液,对pH,温度和CO2有很好的反应能力.
- 在各种实际油相中证明了乳化剂的广泛应用.
- 实现了高的黄素封装效率 (>80%).
- 显著增强自由脂肪酸的释放和黄素的生物可访问性 (约. 增加了4.3倍).
结论:
- 使用基于纤维素纳米晶的纳米颗粒制备多反应性皮克林乳液的有效策略已经建立.
- 开发的皮克林乳液具有显著的潜力,可以改善脂溶性药物和活性化合物的生物可用性.
- 这项研究为可持续纳米材料在先进的乳液技术和药物输送系统中开辟了新的途径.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
139
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
139
01:23Modified-Release Drug Delivery Systems: Classification
318
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
318
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
174
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
174
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165
01:26Oral Drug Delivery Systems: Continuous-Release Systems
319
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
319